Recursion appoints Vicki Goodman as CMO effective April 6, 2026; David Mauro transitions out

RECURSION PHARMACEUTICALS, INC.

Dr. Goodman joins from Mural Oncology as CMO; prior executive roles at Exelixis, Merck, BMS, and GSK.
Outgoing CMO Dr. Mauro will serve as advisor until May 29, 2026, after three years at Recursion.
CEO Najat Khan highlights Goodman's late-stage clinical development experience for advancing pipeline.
Company reiterates key clinical and regulatory milestones consistent with prior expectations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.